Dr. Lal PathLabs Limited

Equities

LALPATHLAB

INE600L01024

Healthcare Facilities & Services

Market Closed - NSE India S.E. Other stock markets 05:10:30 16/07/2024 pm IST			5-day change	1st Jan Change
2,998 ^INR	+0.04%		+2.49%	+16.31%

29/06	Dr. Lal PathLabs Limited Declares Final Dividend for the Financial Year Ended March 31, 2024	CI
14/05	Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505	MT

Dr. Lal PathLabs Limited Declares Final Dividend for the Financial Year Ended March 31, 2024

June 29, 2024 at 05:28 pm IST

Dr. Lal PathLabs Limited announced that at the AGM was held on June 29, 2024, declared final dividend of INR 6/- per fully paid equity share having face value of INR 10/- each for the Financial Year ended March 31, 2024.

Latest news about Dr. Lal PathLabs Limited

Dr. Lal PathLabs Limited Declares Final Dividend for the Financial Year Ended March 31, 2024	29/06	CI
Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505	14/05	MT
Dr. Lal Pathlabs' Fiscal Q4 Consolidated Net Profit Rises; Share Up 6%	13/05	MT
Transcript : Dr. Lal PathLabs Limited, Q4 2024 Earnings Call, May 10, 2024	10/05
India's Dr. LalPath Labs posts higher Q4 profit rises on healthy testing demand	10/05	RE
Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024	10/05	CI
Dr. Lal PathLabs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	10/05	CI
Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024	26/04	CI
Dr Lal Pathlabs Names CEO	18/03	MT
Dr. Lal PathLabs Limited Appoints Shankha Banerjee as Chief Executive Officer, Effective May 21, 2024	17/03	CI
Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer	03/03	CI
Nomura Adjusts Dr. Lal Pathlabs’ Price Target to INR2,505 From INR2,465, Keeps at Neutral	05/02	MT
Dr. Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q3; EPS, Revenue Miss Estimates	02/02	MT
Dr. Lal PathLabs Seeks M&A	01/02	CI
Transcript : Dr. Lal PathLabs Limited, Q3 2024 Earnings Call, Feb 01, 2024	01/02
India's Dr. Lal PathLabs posts 54% jump in Q3 profit on flu, COVID tests	01/02	RE
Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24	01/02	CI
Dr. Lal PathLabs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	01/02	CI
Dr. Lal Pathlabs Board to Consider Second Interim Dividend for Fiscal 2024	25/01	MT
Nomura Upgrades Dr. Lal Pathlabs to Neutral From Reduce, Adjusts Price Target to INR2,465 From INR,2002	06/11	MT
Dr Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q2; Shares Climb 5%	03/11	MT
Transcript : Dr. Lal PathLabs Limited, H1 2024 Earnings Call, Nov 02, 2023	02/11
Dr. Lal PathLabs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	02/11	CI
Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023	12/23/12	CI
Dr. Lal PathLabs Limited Announces Change in Directorate	20/23/20	CI

Chart Dr. Lal PathLabs Limited

Duration

Period

More charts

Company Profile

Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services in India. The Company offers patients and healthcare providers a range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Its tests include Pregnancy Test, Full Body Checkups, Covid 19 Test, Heart Test, Kidney Test, Liver Test, CBC Test, Cholesterol Test, Hepatitis B Test, Kidney Function Test, Liver Function Test, Sugar Test, Thyroid Test, Typhoid Test, Uric Acid Test, Vitamin B12 Test and Vitamin D Test. The Company has approximately 280 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore and Mumbai), 5,762 patient service centers (PSCs) and 11,619 pick-up points (PUPs). Its customers include individual patients, hospitals and other healthcare providers and corporate customers.

Sector

Healthcare Facilities & Services

Calendar

25/07/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Dr. Lal PathLabs Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2,998 INR

Average target price

2,588 INR

Spread / Average Target

-13.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
DR. LAL PATHLABS LIMITED	+16.31%	2.98B
SONIC HEALTHCARE LIMITED	-17.50%	8.55B
RADNET, INC.	+87.40%	4.63B
SYNLAB AG	-3.15%	2.65B
NEOGENOMICS, INC.	-2.10%	1.89B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-53.27%	1.81B
FLEURY S.A.	-12.97%	1.56B
METROPOLIS HEALTHCARE LIMITED	+21.59%	1.27B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-47.96%	1.07B
OPKO HEALTH, INC.	-4.64%	997M

Medical & Diagnostic Laboratories